Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must fulfill all of the following criteria to be eligible for study entry:~* Age 18-80~* Able to provide informed consent~* Biopsy proven unresectable metastatic adenocarcinoma of the colon or rectum~* Documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer~* Radiographically measurable disease with at least one bidimensionally measurable lesion of \> 1 cm~* Prior first-line regimen must have been completed at least 4 weeks prior to study treatment~* Use of biologic agents with first-line chemotherapy permitted~* Previous adjuvant regimens must have been greater than 6 months before inclusion~* Adequate organ function including bone marrow, liver and renal function as defined by the following values: absolute neutrophil count \> 1500/microliter; Hgb \> 9 g/dL; platelets \> 90,000/microliter; International Normalized Ratio \< 1.8 (unless in therapeutic range if taking warfarin or other warfarin-derivative anticoagulants and are being monitored regularly for changes in prothrombin time or International Normalized Ratio); bilirubin \< 2 times the Upper Limit of Normal; alkaline phosphatase \< 3 times the Upper Limit of Normal; aspartate aminotransferase/alanine aminotransferase \< 5 times the Upper Limit of Normal; serum creatinine \< 1.5 times the Upper Limit of Normal~* Eastern Cooperative Oncology Group status \< 2~Exclusion Criteria:~Patients meeting any of the following criteria are ineligible for study entry:~* Prior second-line chemotherapy regimens for colorectal cancer~* Prior treatment with erlotinib or gefitinib~* Central Nervous System metastasis~* Second malignancies less than 5 years prior to enrollment. Completely resected basal or squamous cell carcinoma of the skin is allowed.~* Untreated/unresolved bowel obstruction~* Inability to take oral mediations~* HIV positive~* Pregnancy~* Other uncontrolled medical illnesses~* Current diarrhea \> grade 2~* Symptomatic angina or uncontrolled congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOX with Erlotinib (Type: EXPERIMENTAL): Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
- FOLFIRI with Erlotinib (Type: EXPERIMENTAL): Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.

Based on this trial design, predict the completion outcome and termination type (if applicable).